← Oncology Approval Tracker

FDA DECISION ·

Libtayo

cemiplimab-rwlc · Regeneron Pharmaceuticals

FDA approvalNew or expanded indicationCutaneous squamous cell carcinoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

As adjuvant therapy for adults with cutaneous squamous cell carcinoma at high risk of recurrence after surgery and radiation.

LAMPGEN ANALYSIS

Why it matters

The approval moves PD-1 treatment into the post-surgery and post-radiation setting for high-risk cutaneous disease.

What research teams should watch

Build a referral path from surgery and radiation that captures pathology risk features and treatment completion dates.

PRIMARY RECORDS

Sources